| In a filing exchange filing, the company stated that the inspection was carried out at its second manufacturing facility, located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, India, from 3 November 2025 to 7 November 2025. The inspection concluded with zero Form 483 observations. Mark Saldanha, managing director said, 'The successful outcome of the cGMP inspection by the US FDA is a testament to our ongoing commitment to product quality and regulatory compliance.' Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The company's consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25. Powered by Capital Market - Live News |